Enjoy complimentary customisation on priority with our Enterprise License!
The Cushing Syndrome Market size is estimated to grow by USD 616.66 million at a CAGR of 14.7% between 2023 and 2028. The Pharmaceutical Industry witnesses market growth driven by the aging population, particularly in managing Endocrine Disorders like Cushing syndrome. Age-related factors such as hormonal imbalance and Cortisol Overproduction amplify demand for Diagnosis and Treatment options.
Healthcare Providers emphasize Disease Management through Medical Conditions awareness and Patient Education initiatives. Clinical Research fosters Therapeutic Options development, aligning with Treatment Guidelines and Regulatory Compliance standards. Emerging economies offer significant market opportunities for Pharmaceutical Companies due to expanding Healthcare Infrastructure and rising Disease Awareness. Such factors propel market growth during the forecast period
For More Highlights About this Report, Download Free Sample in a Minute
The type segment is classified into glucocorticoid receptor antagonists, pituitary-directed drugs, and steroidogenesis inhibitors. The distribution channel segment is classified into hospital pharmacy, retail pharmacy, and online pharmacy. The geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW).
The glucocorticoid receptor antagonists segment is estimated to witness significant change during the forecast period. Mifepristone is essentially a US-based FDA-approved drug classified under glucocorticoid receptor antagonists for the treatment of this. It is extensively used to treat high blood sugar associated with this disease. Moreover, glucocorticoid antagonists, or glucocorticoid receptor-directed drugs, represent an alternative treatment for a group of patients with Cushing syndrome.
Get a glance at the market contribution of various segments Download the PDF Sample
The glucocorticoid receptor antagonists segment was the largest segment and was valued at USD 303.49 million in 2018. In addition, glucocorticoid antagonism is rapidly effective in controlling hypercortisolism which in turn, plays an important role in it's management, majorly when the presence of severe disease or concomitant conditions needs a rapid control of cortisol excess. Furthermore, this is associated with diabetes mellitus or glucose intolerance for patients who are not eligible for surgery or who have not responded to prior surgery. As a result, this increases the demand for glucocorticoid receptor antagonists among patients. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 86% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
One of the main factors which is signficantly contributing to the market growth in North America is the rising prevalence in the region. The main country in North America, which has a dominant share in the region, is the US, followed by Canada. Factors such as the availability of counter drugs, including Isturisa (osilodrostat), Korlym (mifepristone), and Recorlev (levoketoconazole) in the region is positively impacting the market growth. Furthermore, the prevalence of this has increased in Canada and Mexico, owing to the increasing number of cases of hormonal disorders caused by poor lifestyle habits. Hence, such factors are driving the market growth in North America during the forecast period.
The market growth is propelled by the aging population and increasing demand for Medications and Surgical Interventions in managing Pituitary Gland Disorders like Cushing syndrome. However, Rare Diseases pose a challenge, with a limited patient pool hindering Research and Development efforts. Despite Healthcare Professionals' dedication to Patient Care and Disease Monitoring, enrollment for Clinical Trials remains challenging.
This scarcity affects Quality Assurance and Brand Recognition, potentially impacting Distribution Channels and Patient Support Group availability. Overcoming this challenge is crucial for sustained market growth during the forecast period.
The Pharmaceutical Industry witnesses market growth driven by the aging population, notably in managing Endocrine Disorders like Hypercortisolism. Age-related factors such as Hormonal Imbalance and Cortisol Overproduction increase demand for Diagnosis and Treatment options, including Medications and Surgical Interventions. This reflects the significant burden of Medical Conditions and Rare Diseases associated with Pituitary Gland Disorders and Adrenal Gland Disorders.
The global prevalence of Hypercortisolism underscores the need for comprehensive Therapeutic Options and Disease Management strategies, driving market growth during the forecast period.
A key factor shaping market growth is the increasing growth potential in emerging economies. The increasing demand for improving patient outcomes through advanced screening and diagnosis of diseases, growing healthcare expenditure, increasing number of hospitals, and increasing incidence of lifestyle diseases are encouraging vendors to establish themselves in developing economies such as India and China, which provides substantial market opportunities. In addition, the increasing number of raw material suppliers, relatively low labor costs, and the low cost of raw materials are the major factors attracting established companies.
Moreover, developing countries such as China and India have large untapped market potential for Cushing syndrome therapeutics manufacturers. In addition, the healthcare industry, including hospitals and clinics in developing economies, is growing at a tremendous pace due to the ongoing demographic shifts and rising healthcare expenditure. Furthermore, the number of hospitals in emerging economies is also propelling the demand for advanced screening and diagnostic procedures. Hence, such factors are positively impacting the market. Therefore, it is expected to drive the market during the forecast period.
A limited patient pool for clinical trials is one of the key challenges hindering market growth. This is one of the rarest diseases that occurs in very few people of the overall population across the world. As a result, this limited number of patients with Cushing syndrome acts as a challenge for investments in the development of new drugs.
Moreover, it becomes very difficult to enroll patients for the clinical evaluation of a drug owing to the limited patient population. Furthermore, even if a drug is of high therapeutic efficacy and has a good safety profile, the clinical trials fail to provide statistically significant results. Therefore, the non-significant results due to the limited patient population result in an increased risk of drug discontinuation during Phase IV or post-marketing surveillance (PMS) studies. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market during the forecast period.
In the realm of endocrinological disorders, Cushing Syndrome stands out, characterized by an array of symptoms stemming from adrenal gland disorders. This syndrome emerges from a cortisol imbalance, often triggered by factors such as a pituitary tumor, excess cortisol production, or abnormalities like adrenal adenoma or adrenal carcinoma.
Treatment options include glucocorticoid therapy to manage symptoms caused by ACTH-secreting tumors or adrenal hyperplasia. However, challenges persist, with patients facing issues like steroid hormone imbalance and various neurological symptoms.
The market for Cushing Syndrome interventions is dynamic, driven by the need to address metabolic disorders like weight gain, hypertension, and osteoporosis, along with mood disorders such as depression and anxiety. Physical manifestations like muscle weakness, fatigue, moon face, and buffalo hump are also crucial considerations.
Moreover, the market addresses cosmetic concerns like hyperpigmentation and hirsutism, as well as reproductive challenges such as menstrual irregularities and insomnia. Electrolyte imbalances further underscore the complexity of managing Cushing Syndrome, necessitating comprehensive solutions to alleviate symptoms and improve patients' quality of life.
Market growth analysis and market research and growth play pivotal roles in understanding the trajectory of the Cushing Syndrome market. Market growth and forecasting, along with market forecasting and market report, provide insights crucial for stakeholders aiming to navigate this evolving landscape.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Corcept Therapeutics Inc: The company offers treatment for Cushing syndrome, such as KORLYM mifepristone 30g tablets.
The research report also includes detailed analyses of the competitive landscape of the market and information about 3 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Cushing Syndrome Market Scope |
|
Report Coverage |
Details |
Page number |
144 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 14.7% |
Market growth 2024-2028 |
USD 616.66 million |
Market structure |
Concentrated |
YoY growth 2023-2024(%) |
12.91 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 86% |
Key countries |
US, Germany, UK, France, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Corcept Therapeutics Inc., Perrigo Co. Plc, Recordati S.p.A, and Xeris Biopharma Holdings Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.